Characterization of the human basilar artery contractile response to 5-HT and triptans

Fundamental and Clinical Pharmacology

Volumn 21, Issue 3, 2007, Pages 265-272

  Silva, Sónia A ^a,b   Marques, Francisco B ^a   Fontes Ribeiro, Carlos A ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

5 HT; 5 HT receptor subtypes; Contractile response; Human basilar artery; Triptans; Western blot analysis

Indexed keywords

3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; ANTIMIGRAINE AGENT; CYANOPINDOLOL; KETANSERIN; NARATRIPTAN; RECEPTOR ANTIBODY; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D ANTAGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; ARTERY CONSTRICTION; ARTICLE; BASILAR ARTERY; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MUSCLE ISOMETRIC CONTRACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; RECEPTOR AFFINITY; SMOOTH MUSCLE CONTRACTION; WESTERN BLOTTING;

BASILAR ARTERY; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN; TRYPTAMINES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 34249046630     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00483.x     Document Type: Article

References (45)

1. Buzzi M.G., Moskowitz M.A. The antimigraine drug sumatriptan (GR 43175), selectively blocks neurogenic plasma extravasation from blood vessels in duramater. Br. J. Pharmacol. (1990) 99 202 206.
2. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. TiPS (1992) 13 307 311.
3. Buzzi M.G., Bonamini M., Moskowitz M.A. Neurogenic model of migraine. Cephalalgia (1995) 15 277 280.
4. Goadsby P.J., Lipton R.B., Ferrari M.D. Migraine - current understanding and treatment. N. Engl. J. Med. (2002) 346 257 270.
5. Villalón C.M., Centurión D., Valdivia L.F., de Vries P., Saxena P.R. Migraine: pathophysiology, pharmacology, treatment and future trenes. Curr. Vasc. Pharmacol. (2003) 1 71 84.
6. Verheggen R., Hundeshagen A.G., Brown A.M., Schindler M., Kaumann A.J. 5-HT1B receptor-mediated contractions in human selective antagonists and 5-HT receptor mRNA expression. Br. J. Pharmacol. (1998) 124 1345 1354.
7. Nilsson T., Longmore J., Shaw D. et al. Characterization of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol. (1999) 372 49 56.
8. Razzaque Z., Heald M.A., Pickard J.D. et al. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F- receptor activation. Br. J. Clin. Pharmacol. (1999) 47 75 82.
9. Humphrey P.P.A., Goadsby P.J. The mode of action of sumatriptan is vascular? A debate. Cephalalgia (1994) 14 401 410.
10. Willet. F., Curzen N., Adams J., Armitage M. Coronary vasospasm induced by subcutaneous sumatriptan. BMJ (1992) 304 1415.
11. Ottervanger J.P., Paalman H.J.A., Boxma G.L., Stricker B.H.Ch. Transmural myocardial infarction with sumatriptan. Lancet (1993) 341 861 862.
12. Cavazos J.E., Caress J.B., Chilukuri V.R. et al. Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet (1994) 343 1105 1106.
13. Knudsen J.F., Friedman B., Chen M., Goldwasser J.E. Ischemic colitis and sumatriptan use. Arch. Intern. Med. (1998) 158 1946 1948.
14. Vijayan N., Peacock J.H. Spinal cord infarction during use of zolmitriptan: a case report. Headache (2000) 40 57 60.
15. Maassen VanDenBrink A., Reekers M., Bax W.A., Ferrari M.D., Saxena P.R. Coronary side-effect potencial of current and prospective antimigraine drugs. Circulation (1998) 98 25 30.
16. Maassen VanDenBrink A., Saxena P.R. Coronary vasoconstrictor potencial of triptans: a review of in vitro pharmacologic data. Headache (2004) 44 (Suppl 1) S13 S19.
17. Lew, M.J., McPherson, G.A. Isolated tissue techniques, in : Garland, C.J. Angus, J.A. (Eds). Pharmacology of vascular smooth muscle, Oxford University Press Inc., New York, 1996, pp. 25 41.
18. Guimarães S., Brandão F., Paiva M.Q. A study of the adrenoceptor-mediated feedback mechanisms by using adrenaline as a false transmitter. Naunyn-Schmiedeberg's Arch. Pharmacol. (1978) 305 185 188.
19. Head R.J., Panek K.R., Reid J., Stitzel R.E., Barone S. o-Methylation of isoproterenol by the endothelium of the rabbit thoracic aorta. Blood Vessels (1986) 23 279 287.
20. Rees D.D., Palmer R.M., Schulz R., Hodson H.F., Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. (1990) 101 746 752.
21. Pauwels P.J., Wurch T., Palmier C., Colpaert F. Pharmacological analysis of G-protein activation mediated by guinea-pig recombinant 5-HT1B receptors in C6-glial cells: similarities with the human 5-HT1B receptor. Br. J. Pharmacol. (1998) 123 51 62.
22. Price G.W., Burton M.J., Collin L.J. et al. SB-216641 and BRL-15,572 - compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. (1997) 356 312 320.
23. Baxter G., Kenneth G., Blaney F., Blackburn T. 5-HT2 receptor subtypes: a family reunited TiPS (1995) 16, 105 110.
24. Geerts I.S., De Meyer G.R.Y., Bult H. Collar-induced elevation of mRNA and functional activity of 5-HT1B receptor in the rabbit carotid artery. Br. J. Pharmacol. (2000) 131 1723 1731.
25. Perry C., Markham A. Sumatriptan - an updated review of its use in migraine. Drugs (1998) 55 889 922.
26. Tfelt-Hansen P., De Vries P., Saxena P. Triptans in migraine - a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs (2000) 60 1259 1287.
27. Parsons A.A., Whalley E.T., Feniuk W., Connor H.E., Humphrey P.P.A. 5-HT1-like receptors mediate 5-hydroxytryptamine-induced contraction of human isolated basilar artery. Br. J. Pharmacol. (1989) 96 434 449.
28. Connor H.E., Feniuk W., Humphrey P.P.A. Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR 43175, a selective 5-HT1-like receptor agonist. Br. J. Pharmacol. (1989) 96 379 387.
29. Hoyer D., Clarke D.E., Fozard J.R. et al. VII International Union of Pharmacology Classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. (1994) 46 157 203.
30. Hartig P.R., Hoyer D., Humphrey P.P.A., Martin G. Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptors subtypes. TiPS (1996) 17 103 105.
31. Parker E.M., Grisel D.A., Iben L.G., Shapiro R.A. A single amino acid differences accounts for the pharmacological distinctions between the rat and human 5-hydroxytryptamine receptors. J. Neurochem. (1993) 60 380 383.
32. Martin G.R. Pre-clinical pharmacology of zolmitriptan (ZomigTM; formely 311C90), a centrally and periopherally acting 5-HT1B/1D agonist for migraine. Cephalalgia (1997) 17 (Suppl. 18) 4 14.
33. Johnson K.W., Schaus J.M., Durkin M.M. et al. 5-HT1F receptor agonists inhibit neurogenoic dural inflammation in guinea pigs. Neuroreport (1997) 8 2237 2240.
34. Bouchelet I., Case B., Olivier A., Hamel E. No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br. J. Pharmacol. (2000) 129 501 508.
35. Peroutka S.J., Kuhar M.J. Autoradiographic localization of 5-HT1 receptors to human and canine basilar arteries. Brain Res. (1984) 310 193 196.
36. Rusch N.J., Chyatte D., Sundt T.M., Vanhoutte P.M. 5-Hydroxytryptamine: source of activator calcium in human basilar arteries. Stroke (1985) 16 718 720.
37. Parsons A.A., Whalley E.T. Evidence for the presence of 5-HT1-like receptors in rabbit isolated basilar arteries. Eur. J. Pharmacol. (1989) 174 189 196.
38. Frenken M. Evidence for two populations of 5-hydroxytrypyamine receptors in dog basilar artery. J. Pharmacol. Exp. Ther. (1989) 250 379 387.
39. Deckert V., Angus J.A. Evidence that 5-HT2 receptors predominantly mediate the contraction of the rat basilar artery to 5-hydroxytryptamine. Eur. J. Pharmacol. (1992) 221 17 25.
40. Miyamoto A., Sakota T., Nishio A. Characterization of 5-hydroxytryptamine receptors on the isolated pig basilar artery by functional and radioligand binding studies. Jpn J. Pharmacol. (1994) 65 265 273.
41. Miyamoto A., Obi T., Nishio A. The vasomotor effects of 5-hydroxytryptamine on equine basilar arteries in vitro. Vet. Res. Commun. (1996) 20 61 70.
42. Verheggen R., Hundeshagen A.G., Brown A.M., Schindler M., Kaumann A.J. 5-HT1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br. J. Pharmacol. (1998) 124 1345 1354.
43. Verheggen R., Meier A., Werner I. et al. Functional 5-HT receptors in human occipital artery. Naunyn-Schmiedeberg's Arch. Pharmacol. (2004) 369 391 401.
44. Cortijo J., Marti-Cabrera M., Bernabeu E. et al. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br. J. Pharmacol. (1997) 122 1455 1463.
45. Karlsson C., Bodelsson G., Bodelsson M., Stjernquist M. Characterization of 5-hydroxytryptamine receptors mediating circular smooth muscle contraction in the human umbilical artery. Gynecol. Obstet. Invest. (1999) 47 102 107.